NGM·Healthcare·$636M·#321 / 520 in Healthcare
STRO Sutro Biopharma, Inc.
37HIGH RISK
CATEGORY BREAKDOWN
GROWTH86
QUALITY0
STABILITY38
VALUATION64
GOVERNANCE12
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+65.2%
86
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
4 months
7
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
-11.8%
100
< 25% strong
Price / Sales
Market cap relative to trailing revenue
6.2x
64
< 3x strong
Rule of 40
Growth rate plus operating margin
-37
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
2.3%
18
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+96.4%
0
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE STRO WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when STRO's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.